Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > BUSINESS
BUSINESS
- Teva Pharma to Temporarily Discontinue Marketing of Risperidone Generics Due to Halt in Bulk Drug Production
November 26, 2012
- Fuji Pharma, Mochida Receive Approvals for Biosimilar Gran
November 26, 2012
- Decline in Sales of Long-listed Drugs Continues with a Double-punch from Generics, NHI Price Reductions
November 26, 2012
- Joint Venture with Actavis to Continue Operations: ASKA Pres. Yamaguchi
November 22, 2012
- Astellas Submits Supplemental NDA in US for Tarceva
November 22, 2012
- MSD to Promote Joint Detailing by Sales Units Specialized in Different Therapeutic Fields: Vice Pres. Kotani
November 22, 2012
- Bayer to Initiate PIII Study of Xarelto for Prevention of MACE in Patients with CAD/PAD, Considers Study in Japan as Well
November 22, 2012
- Japanese Ethical Drug Market Shows Negative Growth in July-September for the First Time in 7 Quarters: IMS Japan
November 21, 2012
- Nexium Dominates HP and GP Markets from October: Rep Track Survey
November 21, 2012
- Sales Up 20% for 3 Major Generic-Only Companies in 1st Half of FY2012
November 21, 2012
- RaQualia to Obtain Substance Patent for APA in Japan
November 20, 2012
- Daiichi Sankyo Files Inavir for Prevention of Influenza Infection
November 20, 2012
- Kyowa Kirin President Hanai Indicates Certain Level of Understanding for “Health Economic Evaluation”
November 20, 2012
- Plan to Expand AZ-BMS Partnership in Diabetes “on Track”: AZ K.K. Pres. Hudson
November 19, 2012
- Toho HD Confident of Achieving 1% Full-Year Operating Profit Rate in Wholesale Business: Vice-President Kono
November 19, 2012
- Novartis to Revamp Marketing Structure in CNS Field, Shift from SOV
November 19, 2012
- Sawai Aims at Top Positions for New Products in Mediceo Utilizing Mediceo’s ARs: President Sawai
November 19, 2012
- E Keppra Grabs 20% Share of Domestic Anti-Epileptic Drug Market; Sales Growing Rapidly
November 19, 2012
- Medical System Network, Hanshin Dispensing Pharmacy to Set Up New Company for Drug Purchase Next April
November 16, 2012
- Nichi-Iko Aims to Initiate PI Study of Herceptin Biosimilar in FY2013: President Tamura
November 16, 2012
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…